Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
about
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibitionEvading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsCompensatory angiogenesis and tumor refractorinessGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsMouse models for studying angiogenesis and lymphangiogenesis in cancerDynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel densityPotent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy.New radiotracers for imaging of vascular targets in angiogenesis-related diseases.Fast rearrangement of the neuronal growth cone's actin cytoskeleton following VEGF stimulation.Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerMDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of RasOptimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.Imaging key biomarkers of tumor angiogenesisPresence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsCurcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signalingTargeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinomaRetreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.Controlling escape from angiogenesis inhibitors.PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently.The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.Angiogenesis in neuroendocrine tumors: therapeutic applications.Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches.Mechanism and Function of Angiogenin in Hematopoietic Malignancy.Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells.CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment.Quantitative phosphoproteomics analysis reveals broad regulatory role of heparan sulfate on endothelial signaling.HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.Microenvironment-mediated resistance to anticancer therapies.Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
P2860
Q24616631-3B4D9794-90AC-4902-BB66-061632E29FC5Q26773795-3C64E558-0853-4B72-9C4C-8CABC4DEC51AQ26851916-91C36733-CDA3-4E06-86AD-FD8BC54A62B0Q26998790-A9DC9613-A47E-4077-9770-0F8632323DF1Q27003898-AEB73356-A569-4C24-8E69-123D2436056EQ27308856-D898BCDA-35FD-45DC-A1C4-40B9C1539F5DQ33557565-2D0AFE19-58AE-48F3-A3F4-7C6E8A63439EQ33981871-F6CC67E0-F837-4CAA-A930-52AFD7034DE7Q34049260-519DE541-6BFD-41F3-92D2-ED50A78EB8BDQ34069720-E8C51571-6F0E-4C26-9536-21AAC559BFE2Q34216877-4494813D-5EE5-44C4-98C8-1CFD4B39B3AEQ34439734-077980B5-6D0D-400E-B72F-232DD3C61EF8Q34806780-340BCD30-88C5-4326-8D71-5EA7A6CAB581Q35028389-760D6CBA-D137-4501-AA79-0D8138EF67F8Q35227104-41F32CD7-3F49-44A4-BE9B-79C8DD8CD892Q35572415-B732F61F-748C-4351-B536-8C5F47F67A9BQ35837949-24F4AFB2-66C5-4B4E-9085-937844E5A27BQ35966757-83BEC737-4F4C-4BCD-9E63-D3C79DF2AEABQ35999557-0BF73B1C-4623-471A-A2E9-19AD4825B4FFQ36094586-AB832785-337B-4ADE-A001-56D9954507DDQ36334053-6F7E3F53-5399-48B4-9334-3DC3AE4DDD22Q36468606-0A9EABBB-A28F-4120-BB6C-9B60F07DAE66Q36762385-61AF47D6-A2DE-488D-9835-CEB0FEA79DAAQ37515231-060CB87E-87DD-4928-8465-9B9B1286F27FQ37640001-910CE306-DE01-44A8-BF11-2D6B1282617BQ37669383-D2F5D88C-393A-4E9F-A104-9BA2484A5B86Q37672654-0F449935-7AAA-49F5-B6E3-B6953DE49A50Q37718460-D3186B15-7F47-4E19-A112-5E6E11B93D28Q37833645-F371C045-560A-4BD8-909A-F15D628E4A2AQ38005887-2846FFB1-A6E4-4942-AEE8-CF4B1D372E25Q38025261-B731017A-2FC4-4F67-8C39-3E3CA25263B5Q38099023-7ABBDE21-24BE-49E9-AF62-5AC380A95F09Q38366707-6C7767CB-E283-4B50-9020-290B4132FB8BQ38757677-6ED1FA33-D886-47E2-B219-0A8D4682A0C4Q38821641-D2FD50C9-F543-4077-AB40-EF4C2050DFC5Q39036931-746C619C-5CF4-4A4A-B14E-B968DC9F800CQ39155470-22F113F2-CE7B-4A41-8D03-CC7BA484B786Q39208364-7FA1915A-C1BF-4237-9B46-47A12FD8B93CQ39286020-E3407577-B493-428F-B6A9-7014EEB70C64Q39570902-D4A497C7-ECBC-4891-9E5A-BADFD6EF40A1
P2860
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor and stromal pathways med ...... to anti-angiogenic therapies.
@en
Tumor and stromal pathways med ...... to anti-angiogenic therapies.
@nl
type
label
Tumor and stromal pathways med ...... to anti-angiogenic therapies.
@en
Tumor and stromal pathways med ...... to anti-angiogenic therapies.
@nl
prefLabel
Tumor and stromal pathways med ...... to anti-angiogenic therapies.
@en
Tumor and stromal pathways med ...... to anti-angiogenic therapies.
@nl
P1476
Tumor and stromal pathways med ...... to anti-angiogenic therapies.
@en
P2093
Napoleone Ferrara
Yongping Crawford
P304
P356
10.1016/J.TIPS.2009.09.004
P577
2009-12-01T00:00:00Z